- Home
- FLNC vs EVO Comparison
FLNC vs EVO Comparison
Compare FLNC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- EVO
- Stock Information
- Founded
- FLNC 2018
- EVO 1993
- Country
- FLNC United States
- EVO Germany
- Employees
- FLNC N/A
- EVO N/A
- Industry
- FLNC Industrial Machinery/Components
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- EVO Health Care
- Exchange
- FLNC Nasdaq
- EVO Nasdaq
- Market Cap
- FLNC 802.6M
- EVO 1.5B
- IPO Year
- FLNC 2021
- EVO 2021
- Fundamental
- Price
- FLNC $8.32
- EVO $4.08
- Analyst Decision
- FLNC Buy
- EVO Buy
- Analyst Count
- FLNC 18
- EVO 2
- Target Price
- FLNC $8.58
- EVO $5.90
- AVG Volume (30 Days)
- FLNC 5.5M
- EVO 117.0K
- Earning Date
- FLNC 08-06-2025
- EVO 08-13-2025
- Dividend Yield
- FLNC N/A
- EVO N/A
- EPS Growth
- FLNC N/A
- EVO N/A
- EPS
- FLNC N/A
- EVO N/A
- Revenue
- FLNC $2,329,871,000.00
- EVO $851,944,444.00
- Revenue This Year
- FLNC $3.61
- EVO $10.08
- Revenue Next Year
- FLNC $25.79
- EVO $10.99
- P/E Ratio
- FLNC N/A
- EVO N/A
- Revenue Growth
- FLNC 6.08
- EVO 1.50
- 52 Week Low
- FLNC $3.46
- EVO $2.84
- 52 Week High
- FLNC $24.00
- EVO $5.64
- Technical
- Relative Strength Index (RSI)
- FLNC 83.84
- EVO 57.98
- Support Level
- FLNC $6.06
- EVO $4.15
- Resistance Level
- FLNC $6.65
- EVO $4.35
- Average True Range (ATR)
- FLNC 0.57
- EVO 0.11
- MACD
- FLNC 0.27
- EVO 0.03
- Stochastic Oscillator
- FLNC 99.55
- EVO 98.39
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.